WRAP53
出典: フリー百科事典『ウィキペディア(Wikipedia)』 (2022/04/04 04:30 UTC 版)
WRAP53(WD40-encoding RNA antisense to p53)は、がんの発生への関与が示唆されている遺伝子である。この遺伝子はp53がん抑制遺伝子を調節するアンチセンスRNAをコードするとともに、DNA修復、テロメアの伸長、カハール体の維持に関与するタンパク質をコードする、という二重の役割を持つ[5][6][7][8]。
- ^ a b c GRCh38: Ensembl release 89: ENSG00000141499 - Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000041346 - Ensembl, May 2017
- ^ Human PubMed Reference:
- ^ Mouse PubMed Reference:
- ^ a b c “Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage”. Molecular Cell 33 (4): 462–71. (February 2009). doi:10.1016/j.molcel.2009.01.028. PMID 19250907.
- ^ “Wrap53, a novel regulator of p53”. Cell Cycle (Georgetown, Tex.) 8 (15): 2343–6. (August 2009). doi:10.4161/cc.8.15.9223. PMID 19571673.
- ^ a b c “A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis”. Science (New York, N.Y.) 323 (5914): 644–8. (January 2009). Bibcode: 2009Sci...323..644V. doi:10.1126/science.1165357. PMC 2728071. PMID 19179534 .
- ^ a b “A conserved WD40 protein binds the Cajal body localization signal of scaRNP particles”. Molecular Cell 34 (1): 47–57. (April 2009). doi:10.1016/j.molcel.2009.02.020. PMC 2700737. PMID 19285445 .
- ^ “CTCF regulates the human p53 gene through direct interaction with its natural antisense transcript, Wrap53”. Genes & Development 28 (7): 723–34. (April 2014). doi:10.1101/gad.236869.113. PMC 4015496. PMID 24696455 .
- ^ a b “WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodies”. PLOS Biology 8 (11): e1000521. (November 2010). doi:10.1371/journal.pbio.1000521. PMC 2970535. PMID 21072240 .
- ^ a b “The scaffold protein WRAP53β orchestrates the ubiquitin response critical for DNA double-strand break repair”. Genes & Development 28 (24): 2726–38. (December 2014). doi:10.1101/gad.246546.114. PMC 4265676. PMID 25512560 .
- ^ “A conserved WD40 protein binds the Cajal body localization signal of scaRNP particles”. Molecular Cell 34 (1): 47–57. (April 2009). doi:10.1016/j.molcel.2009.02.020. PMC 2700737. PMID 19285445 .
- ^ a b c “Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita”. Genes & Development 25 (1): 11–6. (January 2011). doi:10.1101/gad.2006411. PMC 3012932. PMID 21205863 .
- ^ “Dyskeratosis congenita”. Hematology. American Society of Hematology. Education Program 2011: 480–6. (2011). doi:10.1182/asheducation-2011.1.480. PMID 22160078.
- ^ “Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders”. Expert Review of Hematology 6 (3): 327–37. (June 2013). doi:10.1586/ehm.13.23. PMID 23782086 .
- ^ “Proteostatic control of telomerase function through TRiC-mediated folding of TCAB1”. Cell 159 (6): 1389–403. (December 2014). doi:10.1016/j.cell.2014.10.059. PMC 4329143. PMID 25467444 .
- ^ “Correlation between severity and SMN protein level in spinal muscular atrophy”. Nature Genetics 16 (3): 265–9. (July 1997). doi:10.1038/ng0797-265. PMID 9207792.
- ^ “Reorganization of Cajal bodies and nucleolar targeting of coilin in motor neurons of type I spinal muscular atrophy”. Histochemistry and Cell Biology 137 (5): 657–67. (May 2012). doi:10.1007/s00418-012-0921-8. PMID 22302308.
- ^ “SMN in spinal muscular atrophy and snRNP biogenesis”. Wiley Interdisciplinary Reviews. RNA 2 (4): 546–64. (2011). doi:10.1002/wrna.76. PMID 21957043.
- ^ a b “WRAP53 promotes cancer cell survival and is a potential target for cancer therapy”. Cell Death & Disease 2: e114. (January 2011). doi:10.1038/cddis.2010.90. PMC 3077286. PMID 21368886 .
- ^ a b “TCAB1: a potential target for diagnosis and therapy of head and neck carcinomas”. Molecular Cancer 13: 180. (July 2014). doi:10.1186/1476-4598-13-180. PMC 4118648. PMID 25070141 .
- ^ “Overexpression of WRAP53 is associated with development and progression of esophageal squamous cell carcinoma”. PLOS ONE 9 (3): e91670. (2014). Bibcode: 2014PLoSO...991670R. doi:10.1371/journal.pone.0091670. PMC 3953598. PMID 24626331 .
- ^ “WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients”. BMC Cancer 12: 294. (July 2012). doi:10.1186/1471-2407-12-294. PMC 3504514. PMID 22805008 .
- ^ “Nuclear expression of WRAP53β is associated with a positive response to radiotherapy and improved overall survival in patients with head and neck squamous cell carcinoma”. Oral Oncology 51 (1): 24–30. (January 2015). doi:10.1016/j.oraloncology.2014.10.003. PMID 25456005.
- ^ “Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer”. International Journal of Cancer 121 (11): 2532–8. (December 2007). doi:10.1002/ijc.22985. PMID 17683073.
- ^ “Association of common WRAP 53 variant with ovarian cancer risk in the Polish population”. Molecular Biology Reports 40 (3): 2145–7. (March 2013). doi:10.1007/s11033-012-2273-9. PMC 3563948. PMID 23192612 .
- ^ “Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer”. Cancer Research 69 (6): 2349–57. (March 2009). doi:10.1158/0008-5472.CAN-08-2902. PMC 2666150. PMID 19276375 .
- ^ “Large-scale evaluation of candidate genes identifies associations between DNA repair and genomic maintenance and development of benzene hematotoxicity”. Carcinogenesis 30 (1): 50–8. (January 2009). doi:10.1093/carcin/bgn249. PMC 2639030. PMID 18978339 .
- 1 WRAP53とは
- 2 WRAP53の概要
- 3 遺伝子
- 4 臨床的意義
- 5 脚注
Weblioに収録されているすべての辞書からWRAP53を検索する場合は、下記のリンクをクリックしてください。
全ての辞書からWRAP53を検索
- WRAP53のページへのリンク